AbbVie (ABBV) fundamentals: P/E, valuation, undervalued?
AbbVie · Health Care · ref. ETF XLV · price $274.36
In short — AbbVie trades at 77.5× earnings (P/E), 16.9× forward, with a net margin of 9.8 % and revenue growth of +10 %. Read: Cheap for the growth (P/E 17 for ~290% growth (PEG 0.1)).
Is AbbVie stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$274.36+19.7% over range
Oct 14, 25low $197.38 · high $281.12Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
86% recommend buying · 22 analysts
Valuation : Cheap for the growth — P/E 17 for ~290% growth (PEG 0.1)
Valuation
77.5
P/E (price/earnings)
16.9
Forward P/E
0.27
PEG
—
Price/book (P/B)
$484.8B
Market cap
3.54
EPS
Profitability & growth
9.8 %
Net margin
+10 %
Revenue growth
+290 %
Earnings growth
$70.9B
Total debt
AbbVie income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $58.1B | $11.8B | 20.4 % |
| 2023 | $54.3B | $4.9B | 9.0 % |
| 2024 | $56.3B | $4.3B | 7.6 % |
| 2025 | $61.2B | $4.2B | 6.9 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is AbbVie's P/E and is the stock undervalued? What's a good P/E?
AbbVie's P/E is 77.5 (forward 16.9). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is AbbVie profitable?
AbbVie has a net margin of 9.8 % (EPS 3.54). The company is profitable.
Is ABBV stock expensive?
Our read: "Cheap for the growth" — P/E 17 for ~290% growth (PEG 0.1). Cross-check with growth and sector.
💬 A question about AbbVie? The JPI assistant answers using our backtest data.